Today, CDC Director Rochelle P. Walensky, M.D., M.P.H., signed a decision letter recommending that Novavax’s COVID-19 vaccination be utilised as a secondary series option for adolescents aged 12 to 17. This advice follows the FDA’s approval of the vaccine for this age range for emergency use.
Novavax’s COVID-19 vaccine, which is currently accessible, is an essential instrument in the pandemic and offers teenagers with a more familiar form of COVID-19 vaccine technology. Having a variety of vaccinations provides the public, governments, and vaccine providers with greater alternatives and flexibility.
The COVID-19 vaccine from Novavax contains harmless COVID-19 viral proteins as well as an adjuvant, which aids the immune system’s future response to the virus. Vaccines that employ protein subunit technology, such as the Novavax COVID-19 vaccine, have been used in the United States for more than 30 years, beginning with the first approved hepatitis B vaccination.
Other protein subunit vaccines used in the United States today include those to protect against influenza and whooping cough (acellular pertussis).